d-dopa

D-DOPA is an enantiomer of the dopamine precursor L-DOPA . It can be converted to L-DOPAviasequential oxidation and transamination, which are mediated by D-amino acid oxidase (DAAO) and DOPA transaminase, respectively, in rat kidney homogenates.1It reduces the number of dopaminergic neurons in primary rat embryonic mesencephalic cultures in a concentration-dependent manner.2Intraventricular administration of D-DOPA (200 μg/animal) increases striatal dopamine levels in rats.3D-DOPA (20 mg/kg, i.p.) induces contralateral turns in a rat model of Parkinson's disease induced by 6-OHDA .4 1.Wu, M., Zhou, X.-J., Konno, R., et al.D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminaseClin. Exp. Pharmacol. Physiol.33(11)1042-1046(2006) 2.Ling, Z.-D., Pieri, S.C., and Carvey, P.M.Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neuronsClin. Neuropharmacol.19(4)360-365(1996) 3.Karoum, F., Freed, W.J., Chuang, L.-W., et al.D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in ratsBrain Res.440(1)190-194(1988) 4.Moses, J., Siddiqui, A., and Silverman, P.B.Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian ratNeurosci. Lett.218(3)145-148(1996)

Dopamine receptor agonist

Dioctanoylphosphatidic acid sodium (DOPA sodium) is a bioactive phosphatidic acid (PA) derivative serving as a key lipid signaling molecule. Derived from glycerophospholipids via the action of phospholipase D (PLD), it acts as a precursor to diacylglycerol (DAG) and lysophosphatidic acid (LPA). It specifically binds to and activates the FRB domain of the mammalian target of rapamycin (mTOR), thereby promoting mTOR phosphorylation. Additionally, it modulates the respiratory burst in phagocytic cells such as neutrophils. In oncological studies, it has been shown to enhance the viability of gallbladder cancer (GBC) cells inhibited by histone deacetylase inhibitors (HDACI), suggesting a protective role against epigenetic-mediated growth suppression.

Levodopa sodium (L-DOPA) is the metabolic precursor of the neurotransmitter dopamine. It is orally active, capable of crossing the blood-brain barrier, and is rapidly taken up by dopaminergic neurons in the brain where it is converted into dopamine. It exhibits anti-hyperalgesic effects and is commonly used to induce animal models of Parkinson's disease.